2024
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, Ali A, Swaminath A, Okawara G, Ellis P, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiation Oncology 2024, 19: 155. PMID: 39511611, PMCID: PMC11542377, DOI: 10.1186/s13014-024-02546-y.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerOverall survivalDifferentiation factor 15GDF15 levelsLA-NSCLCTumor volumeSurvival outcomesUnresectable locally advanced non-small cell lung cancerLung cancerPhase II randomized clinical trialConcurrent chest radiotherapyIncreased GDF15 levelsUnresectable LA-NSCLCTreated with chemoradiotherapyGross target volumeGrowth differentiation factor 15Platinum-based chemotherapyPlasma GDF15 levelsRandomized to treatmentLevels of GDF15Patient blood plasmaRandomized clinical trials
2023
Molecular Testing in Non–Small-Cell Lung Cancer: A Call to Action
Sathiyapalan A, Ellis P. Molecular Testing in Non–Small-Cell Lung Cancer: A Call to Action. JCO Oncology Practice 2023, 20: 7-9. PMID: 38033274, DOI: 10.1200/op.23.00669.Peer-Reviewed Original ResearchUpdate on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
Sathiyapalan A, Baloush Z, Ellis P. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease. Current Oncology 2023, 30: 9514-9529. PMID: 37999109, PMCID: PMC10670056, DOI: 10.3390/curroncol30110689.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungCombined Modality TherapyDisease-Free SurvivalHumansLung NeoplasmsNivolumabConceptsStage III nonsmall cell lung cancerNonsmall cell lung cancerCurative-intent therapyDisease-free survivalEvent-free survivalPathologic complete responseStandard of careOverall survivalSystemic therapyUnresectable stage III nonsmall cell lung cancerResectable nonsmall cell lung cancerImmune checkpoint inhibitor therapyAddition of durvalumabPalliative systemic therapyBest supportive careCheckpoint inhibitor therapyNeoadjuvant systemic therapyManagement of patientsCell lung cancerConsolidation durvalumabPerioperative therapyConcurrent chemoradiationMultimodality therapySupportive careSurgical resection